Angany’s Unique Peanut Allergy Vaccine: Aiming to Overcome Peanut Allergy via Active Immunotherapy
Time: 9:15 am
day: Day One
- Sharing allergen-bearing Ebioparticles™ mimicking viruses: why and how
- Understanding the safety, efficacy and convenience of vaccinal approach: helping patients beyond the desensitization paradigm
- Considering advantages and ethics of green biomanufacturing treating, curing, or preventing allergy?
- The future: what Angany’s approaches to cancer immunotherapy and allergy immunotherapy have in common